Responsibility in Drug Advertising Act of 2019
United States116th CongressHR-4106House of Representatives
Latest legislative activity: Jul 31, 2019
Summary
Official Summary
Responsibility in Drug Advertising Act of 2019
This bill prohibits direct-to-consumer advertising of a drug in the first three years after the drug's approval. The Food and Drug Administration may (1) waive the third year of this prohibition for a drug if direct-to-consumer advertising of the drug would have an affirmative value to public health, or (2) extend the prohibition if the drug has significant adverse health effects.Bill texts
All available records shown.
Timeline
Latest companion bill action
S-3180: Responsibility in Drug Advertising Act of 2020Introduced in Senate
Introduced in House
Referred to the House Committee on Energy and Commerce.
House of Representatives
Referred to the Subcommittee on Health.
House of Representatives
All available records shown.